• FGFR3 Inhibition in SLC26A2 Chondrodysplasia

  2026-10-13

  A mouse study links excessive FGFR3 signaling to SLC26A2-related skeletal dysplasia and reports partial phenotypic improvement after genetic or pharmacological pathway inhibition. The findings support a preclinical mechanism, but they do not establish efficacy, safety, or clinical applicability in humans.

• Netarsudil and Predictive siRNA Codelivery: Evidence

  2026-10-13

  A 2026 Science Advances study evaluated whether molecular descriptors could predict siRNA complexation by ionizable drugs and identified Netarsudil (AR-13324) as a candidate for codelivery. The reported reduction in CTGF mRNA and actin-network density in fibrotic human trabecular meshwork cells is an early, cell-based finding—not evidence of clinical efficacy, therapeutic synergy, or improved aqueous humor outflow in patients.

• MEK/ERK Signaling in Axolotl Limb Patterning

  2026-10-12

  A 2026 Cell Reports study links asymmetric anterior–posterior gene expression to proximal–distal positional information during axolotl limb regeneration, with ERK signaling implicated as a regulatory connection. U0126-EtOH is relevant as a MEK1/2 pathway research tool, but the supplied evidence does not establish that this specific compound or supplier was used in the study.

• Macrophage EV–miR-660 Signaling in Breast Cancer

  2026-10-12

  A preclinical study links tumor-associated macrophage extracellular-vesicle miR-660 with KLHL21 suppression and NF-κB p65 activation in breast cancer models. The findings provide a mechanistic hypothesis for macrophage–tumor communication, but they do not establish a clinical biomarker, treatment strategy, or role for Arctigenin.

• Losmapimod and the Limits of Dual-Action Claims

  2026-10-11

  A source-grounded overview of Losmapimod (GW856553X), p38 MAPK pharmacology, and what recent structural work does—and does not—show about dual-action kinase inhibition.

• 17-AAG (Tanespimycin): Evidence in Context

  2026-10-10

  17-AAG, also known as Tanespimycin, is a synthetic geldanamycin analogue investigated as an HSP90 chaperone inhibitor in cancer research. This overview distinguishes supplier-reported mechanism and model activity from primary evidence, and explains why the 2025 norovirus study on NINJ1-mediated secretion does not establish an antiviral role for 17-AAG.

• Erlotinib and EGFR–CXCR4 Signaling: Heteromer Insight

  2026-10-09

  Erlotinib, also known as NSC 718781, offers a focused way to interpret EGFR kinase dependence within CXCR4–EGFR receptor complexes. This article examines what the 2026 Comez et al. study establishes, what remains unresolved, and how kinase inhibition can be connected cautiously to signaling and cancer-cell phenotypes.

• H-89 and Wnt–PKA Signaling in Bone Formation

  2026-10-09

  A source-grounded overview of how H-89 may inform research on PKA-linked Wnt signaling, O-GlcNAcylation, glycolysis, and osteogenesis. The discussion separates findings from the 2024 bone study from supplier claims and emphasizes pharmacological specificity, model limitations, and the absence of evidence that H-89 itself is a bone-building therapy.

• ARID1A-Linked Melanoma Resistance Networks

  2026-10-08

  The reference study uses integrative multi-omics and network analysis to examine early drug responses in BRAF-driven melanoma, comparing a sensitive model with an ARID1A-knockout resistant derivative. Its findings connect persistent MAPK and JNK signaling, altered PRKD1 and JUN activity, receptor-kinase changes, and immune-relevant remodeling into a systems-level model of resistance.

• LY2228820 and p38 MAPK Research Evidence

  2026-10-08

  LY2228820 is a research tool for studying p38α/β MAPK signaling, inflammation, stress responses, and cancer biology. The supplied commercial description reports biochemical and preclinical activity, while the cited 2025 airway-stent study evaluated a different combination of anlotinib and silver nanoparticles. This overview separates those evidence streams and defines their applicability limits.

• LDN-193189: BMP Signaling Evidence and Limits

  2026-10-07

  LDN-193189 is a research small molecule used to investigate BMP type I receptor signaling, particularly ALK2 and ALK3. The supplied evidence supports a cautious interpretation: supplier-reported pathway activity provides mechanistic rationale, while the cited mammary-cell study offers important context on TGF-β, Sca-1, plasticity, and Smad signaling but does not, in the supplied material, establish a compound-specific LDN-193189 result.

• CUDC-907 Product Overview

  2026-10-07

  CUDC-907 (SKU A4097) is described by APExBIO as a dual PI3K and HDAC inhibitor for cancer-signaling research. No matched paper evidence was supplied, so this overview is limited to documented product identity and conceptual scope.

• Pexmetinib (ARRY-614): Beyond Dual-Target Inhibition

  2026-10-06

  Pexmetinib (ARRY-614) offers a useful model for interpreting dual-target kinase inhibition across inflammatory and hematologic research. This article distinguishes its p38 MAPK/Tie2 profile from a newer phosphatase-centered concept involving p38α dephosphorylation, clarifying what the evidence supports and where extrapolation should stop.

• Sorafenib Beyond Kinase Potency: Reading Angiogenesis Data

  2026-10-06

  Sorafenib, also known as BAY-43-9006, is more than a multikinase inhibitor: it is a useful cancer biology research tool for separating tumor-cell signaling from vascular effects. This article interprets its antiangiogenic evidence, compares assay contexts, and examines what recent VEGFR-2 inhibitor research can—and cannot—establish.

• Netarsudil: From ROCK Inhibition to siRNA Codelivery

  2026-10-05

  Netarsudil (AR-13324) is more than a ROCK pathway probe: emerging evidence positions it as both a cytoskeletal modulator and an ionizable small-molecule component for siRNA codelivery. This article separates established biology from formulation-specific findings and clarifies the boundaries of translational interpretation.

8518 records 1/568 page Next 12345 下5页 Last page